case_images: PMC6904776_01
case_images: Brain MRI showing multiple enhancing brain lesions including a 0.7-cm right
  superior anterior cerebellar parenchymal lesion (A, arrow), 0.3-cm and
  0.2-cm left paramedian cerebellar vermian lesions (A, dashed arrow), a
  1.9-cm superior right cerebellar lesion with mass effect and surrounding
  vasogenic edema causing partial effacement of the right aspect of the fourth
  ventricle (B), and a 0.2-cm left thalamic lesion (C, arrow).
case_images: 10.1177_2324709619893548-fig1.jpg
case_images: PMC6904776_01_10.1177_2324709619893548-fig1.jpg
case_images: fig1-2324709619893548
case_images: A follow-up brain magnetic resonance imaging (MRI) showed multiple posterior fossa enhancing lesions and an additional punctate enhancing lesion in the left thalamus, suspicious for metastatic carcinoma (Figure 1).
case_images: Brain biopsy showing a cellular infiltrate with necrosis and perivascular
  preservation (A) composed of large lymphoid cells with centralistic
  morphology and numerous apoptotic bodies (B), immunoreactive for CD-20 (C),
  Bcl-6 (D), and CD-10 (E) consistent with a DLBCL of germinal center
  phenotype. The lymphoma exhibited a high proliferation index (>95%).
case_images: 10.1177_2324709619893548-fig2.jpg
case_images: PMC6904776_01_10.1177_2324709619893548-fig2.jpg
case_images: fig2-2324709619893548
case_images: Histopathology of the specimen showed a DLBCL positive for CD20 and CD10 with a Ki67 proliferative index greater than 95% (Figure 2).
case_images: Brain MRI after 6 cycles of chemotherapy completion showing interval
  resolution of the multiple enhancing lesions in the posterior fossa. No
  evidence of residual or new foci of primary CNS lymphoma.
case_images: 10.1177_2324709619893548-fig3.jpg
case_images: PMC6904776_01_10.1177_2324709619893548-fig3.jpg
case_images: fig3-2324709619893548
case_images: A follow-up brain MRI showed interval resolution of the multiple enhancing lesions in the posterior fossa, with no evidence of residual or new foci of primary CNS lymphoma (Figure 3).